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Abstract
Childhood radiation exposure has been associated with increased papillary thyroid carcinoma (PTC) risk. The
role of anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related PTC remains unclear, but
STRN-ALK fusions have recently been detected in PTCs from radiation exposed persons after Chernobyl using
targeted next-generation sequencing and RNA-seq. We investigated ALK and RET gene rearrangements as well
as known driver point mutations in PTC tumours from 77 radiation-exposed patients (mean age at surgery
22.4 years) and PTC tumours from 19 non-exposed individuals after the Chernobyl accident. ALK rearrange-
ments were detected by fluorescence in situ hybridisation (FISH) and confirmed with immunohistochemistry
(IHC); point mutations in the BRAF and RAS genes were detected by DNA pyrosequencing. Among the 77
tumours from exposed persons, we identified 7 ALK rearrangements and none in the unexposed group. When
combining ALK and RET rearrangements, we found 24 in the exposed (31.2%) compared to two (10.5%) in
the unexposed group. Odds ratios increased significantly in a dose-dependent manner up to 6.2 (95%CI: 1.1,
34.7; p5 0.039) at Iodine-131 thyroid doses >500 mGy. In total, 27 cases carried point mutations of BRAF
or RAS genes, yet logistic regression analysis failed to identify significant dose association. To our knowledge
we are the first to describe ALK rearrangements in post-Chernobyl PTC samples using routine methods such as
FISH and IHC. Our findings further support the hypothesis that gene rearrangements, but not oncogenic driver
mutations, are associated with ionising radiation-related tumour risk. IHC may represent an effective method
for ALK-screening in PTCs with known radiation aetiology, which is of clinical value since oncogenic ALK acti-
vation might represent a valuable target for small molecule inhibitors.
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Introduction
The risk of papillary thyroid carcinoma (PTC) has
been clearly associated with a history of ionizing
radiation exposure, especially at young ages [1]. The
higher metabolic activity makes the gland especially
vulnerable to the carcinogenic effects of radioactive
Iodine-131 during childhood and adolescence.
Follow-up after the Chernobyl nuclear accident in
1986 revealed a striking increase in the incidence of
childhood PTC among the population in the highly I-
131 contaminated areas of Belarus and Ukraine. A
strong relation between I-131 thyroid dose and the
risk of PTC has been shown [2,3]. Additionally,
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long-term cohort studies substantiated the strong
association between the risk of PTC and young age
at exposure [2,4,5].
Investigations of the molecular mechanisms possi-
bly underlying PTC revealed mutually exclusive
genetic aberrations that cause constitutive activation
along the MAPK-signalling pathway [6]. Yet, the
molecular profile of PTC appears also to be strongly
influenced by age at diagnosis [7]. While the preva-
lence of point mutations in the BRAF and RAS genes
found in sporadic PTC cases rises simultaneously
with increasing age at diagnosis, chromosomal rear-
rangements of the RET/PTC and TRK genes are more
common in childhood and adolescent PTC cases than
in adult onset PTC [7–13].
As radiation-induced DNA double strand breaks
can cause chromosomal rearrangements, it was
hypothesized that PTC cases diagnosed after radia-
tion exposure could show a high prevalence of such
fusion events. Indeed, some studies of post-
Chernobyl PTC cases revealed an association of
RET/PTC and NTRK rearrangements with individual
I-131 thyroid doses, but up to one-third of radiation-
related tumours harboured none of the known muta-
tions [14]. Efforts have continued to discover other
targets, resulting in the identification of new gene
rearrangements such as PAX8/PPARc, AKAP9/BRAF,
or TPR/NTRK1 [14–18]. Recently, rearrangements of
the anaplastic lymphoma kinase (ALK) gene were
identified in PTCs of atomic bomb survivors and
individuals exposed in the Chernobyl accident, sug-
gesting a possible role of ALK rearrangements in
radiation-related PTC [16,19].
ALK encodes for a membrane tyrosine kinase
receptor, which is physiologically expressed in fetal
neuronal progenitor cells and plays a key role in
cell proliferation, survival, and differentiation [17].
Aberrant non-neuronal expression of ALK caused
by rearrangement events has been shown to drive
the carcinogenesis of various malignancies, includ-
ing anaplastic large cell lymphoma, a subset of
non-small-cell lung cancer (NSCLC) and, more
recently, aggressive forms of thyroid cancer
[15,17,18]. Targeted therapy with ALK inhibitors
like Crizotinib is in clinical use for the treatment
of ALK-rearranged NSCLC and offers a promising
therapeutic option for other ALK-driven tumours
[20]. The diagnosis of ALK rearrangements is
required prior to ALK-inhibiting therapy and can
be routinely performed using immunohistochemis-
try (IHC) or fluorescence in situ hybridisation
(FISH).
In this study, we screened young Ukrainian PTC
patients exposed to I-131 fallout after the Chernobyl
nuclear accident for common driver mutations and
gene rearrangements, including ALK, by DNA pyro-
sequencing, IHC and FISH to investigate whether a
molecular radiation signature can be established
using routine diagnostic techniques.
Materials and methods
DNA and tissue samples
We studied tissue samples from 100 Ukrainian
patients who were diagnosed with PTC and under-
went surgery between 1999 and 2013. Of these, 80
patients were exposed to I-131 fallout during the
Chernobyl accident. Twenty were born after 31
March 1987 and, due to the isotope’s physical half-
life of approximately 8 days, were considered unex-
posed. Pathological diagnoses were performed by
the Institute of Endocrinology and Metabolism
(Kiev, Ukraine) and were reviewed by the Interna-
tional Pathology Panel of the Chernobyl Tissue
Bank (CTB). Preparation of tissue microarrays
(TMA) by arranging formalin-fixed paraffin-embed-
ded (FFPE) archive tissue samples, and isolation of
corresponding tumour DNA, were carried out by the
CTB (CTB project number 002/14). We obtained a
total of nine TMA slides consisting of three differ-
ent TMAs containing cores of varying areas of the
respective tumour.
Sample inclusion and exclusion criteria
We excluded four samples from the study because
tumour tissues from three persons were not present
across all analysed TMA slides and, for one person,
no thyroid dose estimate was available. Pyrosequenc-
ing analysis of point mutations in BRAF or RAS genes
was performed on 95 samples, because an additional
sample lacked a DNA sample. FISH analysis of RET
gene rearrangements was performed using a single
TMA slide and included a total of 69 samples due to
missing cores or unrepresentative tissue. Results for
IHC-testing are based on the analysis of 93 PTCs, rep-
resenting the number of samples present on two TMA
slides stained by IHC.
One sample could not be analysed by FISH as a
consequence of high background fluorescence. This
sample was included in the study and regarded as
ALK-non-rearranged due to negative IHC staining.
I-131 thyroid dose estimates
Individual thyroid doses from I-131 fallout exposure
of persons diagnosed with PTC were estimated by
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the Ukrainian Institute of Radiation Protection (Kiev,
Ukraine) as previously described [21,22]. In brief, for
each CTB donor, 1000 stochastic dose estimates
were calculated while randomly changing values of
uncertain parameters and the resulting arithmetic
mean was used as a single thyroid dose value for sta-
tistical analysis.
Pyrosequencing
Sequence analysis of mutational hot-spot regions in
KRAS, NRAS, and BRAF oncogenes was performed
using the PyroMark Q24 platform and the In Vitro
Diagnostic marked therascreen KRAS, RAS extension,
and BRAF pyro kits according to the instructions of
the manufacturer (Qiagen, Hilden, Germany). In
brief, the respective genetic regions of interest were
amplified using biotin-labelled primers and 10 ng of
patient DNA per PCR approach. After denaturation
and purification steps, the single stranded PCR prod-
ucts were used as templates for sequence analysis.
FISH and IHC analyses
FISH analysis was performed on TMAs using the
ZytoLight
VR
SPEC ALK/EML4 TriCheckTMProbe or
the ZytoLight
VR
SPEC RET Dual Colour Break Apart
Probe. Pre-treatment, denaturation, hybridization as
well as washing steps were performed as recom-
mended by the manufacturer (Zytomed Systems,
Berlin, Germany). For evaluation, at least 50 tumour
cells were taken into account per core. Cases were
considered positive when 15 cells showed break-
apart signals.
ALK-IHC was also conducted on TMA slides
applying the anti-human ALK monoclonal primary
antibody clone 1A4 in a 1:100 dilution (Zytomed
Systems). Heat-induced epitope retrieval was done
in CC1-buffer for 72 min at 95 8C followed by incu-
bation of anti-ALK antibody for 16 min at 37 8C.
Subsequent detection was performed using the Opti-
view DAB IHC Detection Kit. All steps of the IHC
assay were carried out on the Ventana Benchmark
XT System (Ventana Medical Systems, Tucson, AZ,
USA). Estimation of ALK expression was done by
scoring the intensity of cytoplasmic staining in at
least 10% of tumour cells assigning scores from 0
to 31 [23].
Statistics
We examined an association of genetic mutation
and rearrangement frequencies with different expo-
sure categories among our case series. Descriptive
statistics of continuous (n, mean, standard deviation,
min, max) and categorical variables (frequency dis-
tributions) were performed and corresponding P val-
ues (t-test/non-parametric rank sum tests, as well as
chi-square/Fisher’s exact test, where applicable)
were calculated for each of the variables. Dose was
categorised following this categorisation (0, >0–
100, >100–500, >500 mGy) and a categorisation
resulting in an even distribution (0, >0–60, >60–
300, >300 mGy) of thyroid cancer samples among
the dose strata. Frequency distributions of BRAF/
RAS mutations and ALK and RET rearrangements
separately and combined were examined for both
types of dose categorization. Cumulative uncondi-
tional logistic regression analysis was performed on
dose categories as outcome variable. Summed
BRAF/RAS mutations and all rearrangements com-
bined were used as explanatory variables in univari-
ate analysis. To these models, we added potential
confounders such as gender and age at exposure/sur-
gery in order to adjust for their impact on the asso-
ciation of genetic alterations and dose categories.
Odds ratios (ORs), 95% confidence intervals (95%
CIs), and corresponding P values (Wald Chi-square)
were calculated. Cox-proportional hazard regression
models with tumour latency as the time scale was
employed on the exposed group using the lowest
dose group as the reference. Violation of the propor-
tional hazard assumption was examined for each
variable separately. We generated a time-dependent
covariate by creating interactions of the predictors
and a function of latency time and included them in
the model. The model with combined ALK and RET
rearrangements as the explanatory variable was
finally adjusted for gender as a potential confounder
using multivariate models.
All calculations were performed using SAS
(release 9.2, Cary, NC, USA). Data were visualised
using Sigma Plot (Version 13, Systat software
GmbH, Erkrath, Germany).
Results
Characteristics of the PTC cases, exposure, and
biological endpoints
The tumour samples were from 25 male (26%) and
71 female (74%) residents of Ukrainian regions
(oblasts; Table 1). The unexposed group included 19
cases (19.8%) with a mean birth date of 5.2 years
after the Chernobyl accident. All 77 exposed patients
(80.2%) were younger than 18 years at the time of
the accident (mean age5 5.5 years).
y g g
ALK rearrangements in post-Chernobyl PTC samples 3
VC 2018 The Authors The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd
J Path: Clin Res 2018J Pathol Clin Res July 2018; 4: 175–183
177
Most of our unexposed samples were from female
patients (18 of 19, 94.7%) compared to 68.8% of
female patients in the exposed group (p5 0.02; Table
1). About 80–95% of both groups originated either
from the Kiev, Rovno, Sumy, or Zhytomyr oblast
(p5 0.1) and showed a comparable age at surgery
(21.36 4.3 versus 22.46 5.5 years in the unexposed
versus the exposed group, respectively, Table 1). Sur-
gery was performed with an average of 16.9 years
after exposure (62.9; Table 1).
Individual Iodine-131-thyroid doses ranged from
13 mGy to a maximum value of 2560 mGy. The
mean exposure dose was 359 mGy (6481 mGy;
Table 1). We used a standardised categorisation (0,
>0–100, >100–500, >500 mGy) and a categoriza-
tion resulting in an even distribution (0, >0–60,
>60–300, >300 mGy) of the exposed group mem-
bers so that about 25–28% fell into one of the three
dose categories (Table 1).
Among the 96 examined biopsies, we detected 7
ALK rearrangements (ALK1, break-apart or isolated
red signal in FISH analysis) in the exposed group
and none in the unexposed group (Figure 1 and
Table 2). Detailed patient characteristics of the
Table 1. Descriptive characteristics of the radiation unexposed and exposed groups diagnosed with PTC after the Chernobyl accident
Unexposed (n5 19) Exposed (n5 77)
Characteristic Category n % n % P value
Gender
Female 18 94.7 53 68.8
Male 1 5.3 24 31.2 0.02
Oblast
Chercassy 0 0 3 3.9
Chernigov 1 5.3 11 14.3
Kiev 12 63.2 27 35.1
Rovno 3 15.8 8 10.4
Sumy 2 10.5 7 9.1
Zhytomyr 1 5.3 21 27.3 0.14
Age at incidence
n 19 77
Mean 25.2 5.5
SD 4.2 5.1
Min 217.5 0.1
Max 20.9 17.7 NA
Age at surgery
n 19 77
Mean 21.3 22.4
SD 4.3 5.5
Min 9.4 14
Max 26.6 33.7 0.46
Time between exposure and surgery
n 19 77
Mean NA 16.9
SD NA 2.9
Min NA 12
Max NA 25.2 NA
Variable Category (mGy)
Exposed (77)
n % Mean SD Min Max
all 77 100.0 359.1 480.8 13.2 2559.6
Dose categories
>0–100 29 37.7 41.2 19.0 13.2 95.2
>100–500 29 37.7 243.8 106.3 103.5 477.2
>500 19 24.6 1020.2 558.9 501.2 2559.6
>0–60 24 31.2 34.0 10.2 13.2 58.9
>60–300 27 35.1 172.8 73.3 62.5 288.5
>300 26 33.7 852.5 552.2 302.4 2559.6
NA, not applicable; SD, standard deviation.
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seven ALK rearranged cases are illustrated in sup-
plementary material, Table S1. The mean ages at
incidence of ALK translocated patients (4.4 years)
and of patients harbouring no ALK rearrangement
(5.4 years) did not differ significantly (p5 0.91).
The ALK rearrangement was found in about 9.4%
of exposed female and 8.3% of exposed male
patients. In two of the ALK1 cases, nuclear distri-
bution of the ALK split and EML4 probe signals in
FISH analysis supported a classification as an
ALK-EML4 gene fusion (Figure 1). Among 69
examined biopsies, we detected 19 RET rearrange-
ments in 33.3% of females and males of the
exposed group, but only 11.1% of females of the
unexposed group (p5 0.07–0.08; Table 2, right
panel). These borderline significant differences in
the frequency distributions remained (p5 0.07)
after combining the ALK and RET rearrangements
resulting in a total number of 26 translocations
with a similar distribution (30.2–33.3%) among
both genders (Table 2). In 95 examined biopsies, 27
point mutations [1 3 KRAS (Q61R), 1 3 KRAS
(G13R), 1 3 NRAS (Q61R), 24 x BRAF (V600E)]
were detected in about one-third of exposed and unex-
posed females and males (p5 0.1–0.9; Table 2).
Association of biological endpoints with dose
About 50% of all BRAF/RAS mutations were detected
in the lowest dose category, and frequencies around
15–20% were observed at higher dose categories and
in the unexposed group (Table 3). These differences
were of borderline significance (p5 0.07–0.1; Table
3). ALK rearrangements showed a non-significant dif-
ference in frequency distribution. Almost 60% of the
rearrangements were observed in the >100–500 mGy
or the >60–300 mGy dose band (Table 3). RET
rearrangements and combined rearrangements of the
ALK and RET genes were statistically significant
(p5 0.047) or of borderline significance (p5 0.06–0.1)
as well as increased in frequency with increasing dose.
The observed rearrangement frequencies increased
about four-fold compared to the unexposed group
(Table 3). These borderline significant associations
remained in logistic regression analysis with adjust-
ment for gender (but not for RAS mutations, data
not shown) and ORs increased in a dose dependent
manner, up to six-fold, and became significant
(p5 0.04–0.05) after exposure >100 mGy when
combining ALK and RET rearrangement frequencies
(Table 4). Neither gender (adjusted or stratified) nor
age at exposure or age at surgery contributed signif-
icantly to this association (data not shown). Also,
these associations were consistent irrespective of the
dose cut-point distributions used. Combined ALK
and RET translocations showed a significant
(p5 0.009) hazard ratio of 2.74 (95% CI: 1.29–
5.83), to which gender did not contribute signifi-
cantly (data not shown).
Immunohistochemistry
All FISH-positive ALK rearrangements were confirmed
by IHC (strong homogenous ALK staining intensity of
the tumour cells—score 21 or 31). Moreover, IHC
staining of two FISH-negative cases highlighted aber-
rant expression of the ALK protein, eliciting a sensitiv-
ity of 100% and a specificity of 98% for the ALK
antibody that was used in this study (clone 1A4). One
of the two ALK-IHC1/ALK-FISH– cases was derived
Table 2. Frequency of genetic alterations based on FISH and
pyrosequencing
Unexposed
(n5 19)
Exposed
(n5 77)
P valueGenetic alteration Category n % n %
ALK rearrangement frequency (FISH)
All Yes 0 0.0 7 9.1
No 19 100.0 70 90.9 0.2
Females Yes 0 0.0 5 9.4
No 18 100.0 48 90.6 0.2
Males Yes 0 0.0 2 8.3
No 1 100.0 22 91.7 0.8
ALK & RET rearrangement frequencies (FISH)
All Yes 2 10.5 24 31.2
No 17 89.5 53 68.8 0.07
Females Yes 2 11.1 16 30.2
No 16 88.9 37 69.8 0.1
Males Yes 0 0.0 8 33.3
No 1 100.0 16 66.7 0.5
Unexposed
(n5 19)
Exposed
(n5 76)
P valueCategory n % n %
Point mutations (KRAS, NRAS, BRAF)
All Yes 6 31.6 21 27.6
No 13 68.4 55 72.4 0.7
Females Yes 5 27.8 15 28.9
No 13 72.2 37 71.1 0.9
Males Yes 1 100.0 6 25.0
No 0 0.0 18 75.0 0.1
Unexposed
(n5 18)
Exposed
(n5 51)
P valueCategory n % n %
RET rearrangement frequency (FISH)
All Yes 2 11.1 17 33.3
No 16 88.9 34 66.7 0.07
Females Yes 2 11.1 11 33.3
No 16 88.9 22 66.7 0.08
Males Yes 0 0.0 6 33.3
No 0 100.0 12 66.7 NA
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from a patient who received a thyroid dose of 103
mGy and showed heterogeneous and weak staining
intensity (score 11). The second tissue sample, which
originated from an unexposed patient, displayed
strong but heterogeneous ALK staining of PTC cells
(score 21).
Discussion
In our study, we verified the presence of ALK rearrange-
ments in a subset of post-Chernobyl patients who
developed PTC after childhood exposure to radioiodine,
but not among unexposed young Ukrainian PTC patients.
In combination with the results for RET rearrangements,
our findings confirm a significant association between
calculated thyroid doses and the presence of gene rear-
rangements in PTCs, supporting results from previous
studies [14,16,19,24,25]. On the contrary, point mutations
of the BRAF and RAS genes that are frequently detected
among sporadic adult PTCs were not associated with
dose.
Previously, the prevalence of genetic alterations in
PTC has been associated with age at diagnosis or
Figure 1. Detection of ALK rearrangements using FISH and IHC. (A) Upper panel: An ALK rearranged case; lower panel: an ALK non-
rearranged case (scale bar: 50 mm). (B) A case exhibiting a FISH signal constellation assigned specifically to an EML-ALK-inversion.
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surgery. In young PTC patients, mutually exclusive
recombinations of genes like RET/PTC, NTRK1,
PAX8/PPARc, or AKAP9/BRAF represent the main
oncogenic drivers, whereas BRAF or RAS point muta-
tions were found in PTC at older age at onset [7].
However, the relevance of ALK rearrangements for
increased risk of childhood PTC remains unclear.
The largest assembly of PTC cases that had been
studied so far showed an overall frequency of ALK
rearrangements of 0.8%, but that study included
mainly adults with a mean age of 46 years [8]. Inter-
estingly, a recent study revealed five ALK gene alter-
ations in 65 radiation-exposed PTC cases as shown
by next-generation sequencing and RNA-seq (7.7%)
with younger age at surgery, supporting our hypothe-
sis of higher frequencies of ALK rearrangements in
PTC among children with radiation aetiology [19].
Pyrosequencing analysis of 95 DNA samples
extracted from PTC tissue revealed a total of 27
BRAF/RAS mutations (28.4%), of which BRAF-
V600E mutations were most frequent (n5 24,
88.8%). PTC patients with BRAF/RAS mutations
were older at the date of surgery (p5 0.01), in line
with previous studies that showed a relationship
between point mutations and age at diagnosis of PTC
[8,14]. In our study, statistical analysis of a potential
association between BRAF/RAS-positive tumours and
dose failed to reach statistical significance. In sum-
mary, our findings strengthen the hypothesis that
oncogenic point mutations are involved in the patho-
genesis of sporadic PTC, which are frequently diag-
nosed at older ages, and lack a clear association with
radiation-related PTC.
Table 3. Frequency distribution of mutations and gene rearrangements by dose categories
Category (mGy)
All BRAF/RAS mutations ALK rearrangements
No (n5 68) Yes (n5 27) No (n5 89) Yes (n5 7)
Variable n % n % Chisq n % n % Chisq
Dose categories
0 13 19.1 6 22.2 19 21.4 0 0.0
>0–100 16 23.5 13 48.2 28 31.5 1 14.3
>100–500 24 35.3 4 14.8 25 28.1 4 57.1
>500 15 22.1 4 14.8 0.07 17 19.1 2 28.6 0.24
0 13 19.1 6 22.2 19 21.4 0 0.0
>0–60 13 19.1 11 40.7 24 27.0 0 0.0
>60–300 22 32.4 4 14.8 23 25.8 4 57.1
>300 20 29.4 6 22.2 0.10 23 25.8 3 42.9 0.10
RET rearrangements ALK and RET rearrangements
No (n5 50) Yes (n5 19) No (n5 70) Yes (n5 26)
n % n % Chisq n % n % Chisq
Dose categories
0 16 32.0 2 10.5 17 24.3 2 7.7
>0–100 16 32.0 4 21.1 24 34.3 5 19.2
>100–500 10 20.0 7 36.8 18 25.7 11 42.3
>500 8 16.0 6 31.6 0.10 11 15.7 8 30.8 0.047
0 16 32.0 2 10.5 17 24.3 2 7.7
>0–60 14 28.0 4 21.1 20 28.6 4 15.4
>60–300 9 18.0 7 36.8 16 22.9 11 42.3
>300 11 22.0 6 31.6 0.15 17 24.3 9 34.6 0.06
Chisq, Chi-square.
Table 4. Association of rearrangements (ALK and RET) with radi-
ation dose among PTC cases after the Chernobyl accident
Model
Dose categories
(mGy) OR 95% CI P value
ALK and RET
rearrangements
0 1
>0–100 1.8 0.3 10.2 0.53
>100–500 5.2 1.0 26.9 0.050
>500 6.2 1.1 34.7 0.039
0.06
ALK and RET
rearrangements
0 1
>0–60 1.7 0.3 10.4 0.57
>60–300 5.8 1.1 30.5 0.036
>300 4.5 0.8 24.0 0.078
0.08
CI, confidence interval; OR, odds ratio.
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RET-FISH revealed 19 RET rearrangements out of
69 analysable cases (27.5%). Non-analysable/missing
tissue samples were mainly from exposed individuals,
so this may be an under-estimate of the effect of ion-
izing radiation. Nevertheless, our findings align with
the expectation that RET gene fusions are frequently
detected in sporadic and to an even higher extent in
radiation-related childhood PTC [7,14,19].
Three-colour FISH analysis of PTC tissue samples
revealed ALK rearrangements in exposed cases only.
Indeed, the 7 identified ALK-rearranged cases (out of
77 exposed patients, 9.1%) were observed among those
with individual thyroid doses from 62 mGy up to 1085
mGy, for which a borderline significant frequency dis-
tribution was seen (p5 0.10). Of note, in two of the
FISH-positive cases, the ALK-EML4 split/fusion signals
were so distinct that we classified these cases as har-
bouring an ALK-EML4 inversion. This type of rear-
rangement has been previously detected in aggressive
BRAF-wild type PTC and, interestingly, the patient in
that report had undergone radioiodine therapy and
external beam radiation [26]. In the other cases, a dis-
tinction between ALK-EML4 or the previously reported
ALK-STRN rearrangement could not be verified based
on FISH analysis alone [15]. This limitation is due to
the relatively close proximity of the EML4 and STRN
genes on the short arm of chromosome 2. To assess the
role of ALK IHC in the detection of ALK gene rear-
rangement, we also performed IHC using a commercial
ALK-antibody (clone 1A4) which is in diagnostic use
for routine ALK testing in lung cancer [23]. IHC stain-
ing of the ALK receptor tyrosine kinase confirmed the
findings from ALK-FISH and provided no false-
negative results. However, two FISH-negative cases
had to be considered positive for ALK staining, repre-
sented by one borderline case from an exposed patient
and a second clearly ALK-positive tissue sample from
a patient lacking radiation aetiology. This may not be
unexpected since a recent study demonstrated discord-
ant FISH results for NSCLC cases with positive ALK
IHC staining [27]. This may be due to the fact that
aberrant ALK protein expression as shown by ALK
IHC may not solely be ascribed to genetic alterations
such as gene fusion or translocation/inversion events,
but also to various pathological modifications along
mutational, epigenetic, splicing, or transcriptional proc-
esses. Interestingly, beneficial ALK inhibitor treatment
was reported in a FISH negative and IHC positive
NSCLC patient, demonstrating the clinical relevance of
ALK IHC screening [28].
Previous studies have revealed an association of
ALK rearrangements with aggressive subtypes of thy-
roid cancer such as poorly differentiated thyroid car-
cinoma or anaplastic thyroid carcinoma [8,15,29].
Regarding the confirmed association between ALK
rearrangements and previous exposure to ionizing
radiation, our findings suggest ALK IHC as a suita-
ble and cost-effective screening method for potential
drug targeting of ALK rearrangements, particularly
among PTC patients with former therapeutic or acci-
dental radiation exposure. Even for sporadic PTC
where ALK rearrangements have been shown to dis-
play low-frequency occurrence, ALK IHC testing of
thyroid cancer cases which fail to respond to conven-
tional therapy like surgery or I-131 treatment might
be advisable.
Our findings support the hypothesis that radiation-
related gene fusions trigger the pathogenesis of child-
hood PTC. In our study of PTC tissue samples after
the Chernobyl accident, including a non-exposed
group, we confirmed an association between rear-
rangements of the ALK and RET genes, but not for
BRAF or RAS point mutations with thyroid gland
exposure to I-131. Taking into account that ALK-
targeted therapy is clinically available, ALK IHC
may offer a cost-effective screening method espe-
cially among PTC patients with known radiation
exposure and resistance to conventional therapy.
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